Generic placeholder image

Mini-Reviews in Medicinal Chemistry


ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Cardiovascular Effects of Glucagon-Like Peptide 1

Author(s): A. Papazafiropoulou, S. I. Pappas, D. Papadogiannis and N. Tentolouris

Volume 11, Issue 1, 2011

Page: [97 - 105] Pages: 9

DOI: 10.2174/138955711793564033

Price: $65


Glucagon-like peptide-1 (GLP-1) is involved in satiety control and glucose homeostasis. Besides, GLP-1 has cardiovascular effects. In experimental models, GLP-1 increases cardiac output and exerts a direct vasodilatory effect. In animals with dilated cardiomyopathy GLP-1 improves left ventricular performance. Human data demonstrated that GLP-1 reduces arterial blood pressure, improves endothelial function in individuals with diabetes and left ventricular function in patients with heart failure. Administration of GLP-1 increases ejection fraction in acute myocardial infraction and reduces ischemia-reperfusion myocardial injury. Although more research is needed, these data suggest that GLP-1 may be used with promising results in patients with heart failure, acute myocardial infarction and revascularization procedures in addition to the standard therapy.

Keywords: Arterial blood pressure, cardiovascular, endothelium, glucagon-like peptide 1, heart failure, left ventricular function, type 2 diabetes mellitus, GLP-1, T2DM, cell proliferation, insulin resistant and hyperlipidemic, glomerulosclerosis, angiotensin II, Bilateral vagotomy, hyperglycemia, dilated cardiomyopathy, norepinephrine, cediranib, thrombolysis, angioplasty, low-flow ischaemia, flow mediated vasodilatation, LVEF, acetylcholine, acute occlusive ischemia

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy